Empowered Funds LLC Takes Position in Denali Therapeutics Inc. (NASDAQ:DNLI)

Empowered Funds LLC acquired a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 18,587 shares of the company’s stock, valued at approximately $379,000.

A number of other large investors have also added to or reduced their stakes in DNLI. CWM LLC increased its position in Denali Therapeutics by 43.6% in the 3rd quarter. CWM LLC now owns 2,153 shares of the company’s stock valued at $63,000 after acquiring an additional 654 shares during the period. Quest Partners LLC bought a new stake in shares of Denali Therapeutics in the third quarter worth $73,000. Assetmark Inc. increased its holdings in Denali Therapeutics by 18.0% in the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock valued at $111,000 after purchasing an additional 580 shares during the period. KBC Group NV increased its holdings in Denali Therapeutics by 75.8% in the fourth quarter. KBC Group NV now owns 6,334 shares of the company’s stock valued at $129,000 after purchasing an additional 2,731 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Denali Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after purchasing an additional 920 shares during the last quarter. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Price Performance

Shares of Denali Therapeutics stock opened at $21.59 on Friday. The business has a 50-day simple moving average of $21.67 and a 200 day simple moving average of $24.67. Denali Therapeutics Inc. has a one year low of $14.56 and a one year high of $33.33. The firm has a market capitalization of $3.11 billion, a price-to-earnings ratio of -7.82 and a beta of 1.43.

Analyst Ratings Changes

A number of equities research analysts have commented on DNLI shares. Baird R W upgraded Denali Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 7th. The Goldman Sachs Group decreased their target price on shares of Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Denali Therapeutics in a research report on Tuesday, February 11th. They issued a “buy” rating and a $31.00 price target on the stock. Robert W. Baird started coverage on shares of Denali Therapeutics in a research report on Tuesday, January 7th. They set an “outperform” rating and a $31.00 price objective for the company. Finally, William Blair restated an “outperform” rating on shares of Denali Therapeutics in a report on Wednesday, January 15th. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.42.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, Director Steve E. Krognes sold 3,339 shares of the company’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total transaction of $69,484.59. Following the transaction, the director now owns 25,757 shares in the company, valued at approximately $536,003.17. This represents a 11.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Vicki L. Sato sold 3,080 shares of Denali Therapeutics stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total transaction of $64,402.80. Following the transaction, the director now owns 107,976 shares of the company’s stock, valued at $2,257,778.16. This represents a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 47,940 shares of company stock valued at $973,442. Company insiders own 7.90% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.